Vaxcyte Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 254

Employees

  • Stock Symbol
  • PCVX

Stock Symbol

  • Share Price
  • $68.76
  • (As of Friday Closing)

Vaxcyte General Information

Description

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.

Contact Information

Website
www.vaxcyte.com
Formerly Known As
SutroVax
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Stock Exchange
NAS
Corporate Office
  • 825 Industrial Road
  • Suite 300
  • San Carlos, CA 94070
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaxcyte Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$68.76 $69.27 $44.20 - $82.04 $7.48B 109M 694K -$3.43

Vaxcyte Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 6,354,329 4,723,790 3,444,656 978,348
Revenue 0 0 0 0
EBITDA (500,084) (461,973) (229,239) (98,614)
Net Income (436,824) (402,266) (223,485) (100,077)
Total Assets 2,091,305 1,407,917 1,006,178 324,337
Total Debt 27,420 29,224 17,941 16,783
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vaxcyte Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vaxcyte‘s full profile, request access.

Request a free trial

Vaxcyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Vaxcyte‘s full profile, request access.

Request a free trial

Vaxcyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients sufferi
Drug Discovery
San Carlos, CA
254 As of 2023
00.000
00000000 00.000

00000

is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000000000000
Lund, Sweden
000 As of 0000
00000
000000000 00000

000000

eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
Pittsburgh, PA
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vaxcyte Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Hansa Biopharma Corporation Lund, Sweden 000 00000 000000000 00000
CytoAgents Venture Capital-Backed Pittsburgh, PA 00 000.00 000000000 000.00
Abivax Formerly PE-Backed Paris, France 00 00000 000000000 00 00000
Vyriad Venture Capital-Backed Rochester, MN 00 00000 00000000000 00000
Visterra Formerly VC-backed Waltham, MA 000 00000 000000&0 00000
You’re viewing 5 of 38 competitors. Get the full list »

Vaxcyte Patents

Vaxcyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3230594-A1 Stabilization of adjuvanted vaccine compositions and their use Pending 02-Sep-2021 0000000000
CA-3208716-A1 Purification processes for polysaccharides and polypeptide conjugates thereof Pending 17-Feb-2021 0000000000
AU-2022221621-A1 Purification processes for polysaccharides and polypeptide conjugates thereof Pending 17-Feb-2021 0000000000
EP-4294452-A1 Purification processes for polysaccharides and polypeptide conjugates thereof Pending 17-Feb-2021 0000000000
JP-2024506713-A Method for purifying polysaccharides and their polypeptide conjugates Pending 17-Feb-2021 A61K47/646
To view Vaxcyte’s complete patent history, request access »

Vaxcyte Executive Team (14)

Name Title Board Seat Contact Info
Grant Pickering Co-Founder, Director and Chief Executive Officer
Andrew Guggenhime President and Chief Financial Officer
Jim Wassil Chief Operating Officer & Executive Vice President
Whitney Jones Chief People Officer
Alan Kimura MD Chief Medical Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Vaxcyte Board Members (21)

Name Representing Role Since
Agustin Mohedas Ph.D Janus Henderson Investors Board Observer 000 0000
Annie Drapeau Self Board Member 000 0000
Carlos Paya Ph.D Self Chairman & Board Member 000 0000
Francesco De Rubertis Ph.D Medicxi Board Observer 000 0000
Halley Gilbert JD Vaxcyte Board Member 000 0000
You’re viewing 5 of 21 board members. Get the full list »

Vaxcyte Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vaxcyte Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vaxcyte‘s full profile, request access.

Request a free trial

Vaxcyte ESG

Risk Overview

Risk Rating

Updated May, 24, 2023

26.27 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 928

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 407

Rank

00.00

Percentile

To view Vaxcyte’s complete esg history, request access »

Vaxcyte FAQs

  • When was Vaxcyte founded?

    Vaxcyte was founded in 2013.

  • Who is the founder of Vaxcyte?

    Ashish Khanna Ph.D and Grant Pickering are the founders of Vaxcyte.

  • Who is the CEO of Vaxcyte?

    Grant Pickering is the CEO of Vaxcyte.

  • Where is Vaxcyte headquartered?

    Vaxcyte is headquartered in San Carlos, CA.

  • What is the size of Vaxcyte?

    Vaxcyte has 254 total employees.

  • What industry is Vaxcyte in?

    Vaxcyte’s primary industry is Drug Discovery.

  • Is Vaxcyte a private or public company?

    Vaxcyte is a Public company.

  • What is Vaxcyte’s stock symbol?

    The ticker symbol for Vaxcyte is PCVX.

  • What is the current stock price of Vaxcyte?

    As of 24-May-2024 the stock price of Vaxcyte is $68.76.

  • What is the current market cap of Vaxcyte?

    The current market capitalization of Vaxcyte is $7.48B.

  • Who are Vaxcyte’s competitors?

    Hansa Biopharma, CytoAgents, Abivax, Vyriad, and Visterra are some of the 38 competitors of Vaxcyte.

  • What is Vaxcyte’s annual earnings per share (EPS)?

    Vaxcyte’s EPS for 12 months was -$3.43.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »